Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
NCT07281599 · View on ClinicalTrials.gov ↗
Study Summary
The EQUIP Study is testing whether high-risk human papillomavirus (hrHPV), the virus that causes most cervical cancers, can be accurately detected from menstrual blood collected at home. People who have been referred for colposcopy after an abnormal Pap or hrHPV test will use the Q-Pad Kit during their period to collect menstrual samples on a special menstrual pad and mail them to a central laboratory for hrHPV testing. The same participants will have a standard cervical sample collected for routine hrHPV testing and will undergo colposcopy as part of their usual care. By comparing hrHPV results from menstrual samples with results from cervical samples and biopsy findings, the study will evaluate how well the Q-Pad hrHPV Test System detects cervical precancer and will also assess how easy and acceptable it is for participants to use this at-home collection method.
Conditions Studied
Interventions
- DEVICE Q-Pad hrHPV Test System
Study Locations (4)
Connecticut
- Planned Parenthood of Southern New England — New Haven
Minnesota
- Planned Parenthood North Central States — Minneapolis
Ohio
- Planned Parenthood of Greater Ohio (PPGOH) — Akron
Utah
- Planned Parenthood Association of Utah — Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2025-12-01 |
| Est. Completion | 2027-03 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07281599
The ClinicalTrials.gov registry entry for NCT07281599 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qurasense, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with HPV appearing as the primary indexed condition, and to 1 intervention — of which Q-Pad hrHPV Test System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07281599 reports 4 study locations spanning 4 distinct geographic areas — top geographies include Connecticut, Minnesota, Ohio. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07281599 about?
NCT07281599 is a clinical study titled "Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer". The EQUIP Study is testing whether high-risk human papillomavirus (hrHPV), the virus that causes most cervical cancers, can be accurately detected from menstrual blood collected at home. People who have been referred for colposcopy after an abnormal Pap or hrHPV test will use the Q-Pad Kit during th...
What is the current status of trial NCT07281599?
This trial is currently recruiting. It is a NA study. The enrollment target is 450 participants. The study started on 2025-12-01. Estimated completion is 2027-03.
What conditions does trial NCT07281599 study?
This clinical trial studies the following conditions: HPV, HPV Infection, Cervical Cancer Screening, HPV 16 Infection, High Risk HPV. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07281599?
The interventions under investigation include: Q-Pad hrHPV Test System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07281599?
This trial is sponsored by Qurasense, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07281599 being conducted?
This trial has 4 study locations across Connecticut, Minnesota, Ohio, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.